Investigational drug · Phase 2
AVD-104
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Geographic Atrophy of the Macula, Macular Degeneration.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "AVD-104"
First trial start
2023
May 2, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AVD-104", any sponsor or status.
Conditions studied
As listed on its trial records.
- Geographic Atrophy of the Macula
- Macular Degeneration
Approved drugs for the same conditions: Wet macular degeneration · Geographic atrophy · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "AVD-104" as an intervention, largest first.
- A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)Pivotal-lookingCompleted
Aviceda Therapeutics, Inc.Industry
NCT05839041 · 300 participants · Start May 2, 2023 · Primary completion Feb 18, 2026
Drug: AVD-104; Avacincaptad · For: Geographic Atrophy of the Macula; Macular Degeneration
Sites: Gilbert, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 56 sites in all
Aviceda Therapeutics, Inc.Industry
NCT06181227 · 21 participants · Start Nov 30, 2023 · Primary completion Apr 5, 2024
Drug: AVD-104 · For: Diabetic Macular Edema; Diabetic Retinopathy
Sites: Erie, Pennsylvania; Dallas, Texas; Wichita Falls, Texas
Newest research
PubMed records naming it or its code names, newest first.
- Multifocal Electroretinography Outcomes Following AVD-104 Treatment for Geographic Atrophy.
Macha NN, Yu M, Naqvi S, et al. · J Vitreoretin Dis 2026
- Investigational drugs in clinical trials for macular degeneration.
Tolentino MJ, Tolentino AJ · Expert Opin Investig Drugs 2022
Also in development for Geographic Atrophy of the Macula
- GAL-101Phase 21 trial
Galimedix Therapeutics Inc · Geographic Atrophy of the Macula
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.